Wuxi Biologics (Shanghai) Co. Technographics

Discover the latest software purchases and digital transformation initiatives being undertaken by Wuxi Biologics (Shanghai) Co. and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 1800 Wuxi Biologics (Shanghai) Co. employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.

During our research, we have identified that Wuxi Biologics (Shanghai) Co. has purchased the following applications: Amazon S3 for Cloud Storage in 2022, Hubspot CRM for CRM in 2021 and the related IT decision-makers and key stakeholders.

Our database provides customer insight and contextual information on which enterprise applications and software systems Wuxi Biologics (Shanghai) Co. is running and its propensity to invest more and deepen its relationship with Amazon Web Services (AWS) , Cloudflare , Quantil or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.

We have been analyzing Wuxi Biologics (Shanghai) Co. revenues, which have grown to $400.0 million in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Wuxi Biologics (Shanghai) Co. intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.